BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26298430)

  • 1. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.
    Knutson KL; Maurer MJ; Preston CC; Moysich KB; Goergen K; Hawthorne KM; Cunningham JM; Odunsi K; Hartmann LC; Kalli KR; Oberg AL; Goode EL
    Cancer Immunol Immunother; 2015 Dec; 64(12):1495-504. PubMed ID: 26298430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
    Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
    PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Zhu Q; Wu X; Wu Y; Wang X
    Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
    Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
    J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.
    Bu M; Shen Y; Seeger WL; An S; Qi R; Sanderson JA; Cai Y
    Tumour Biol; 2016 Mar; 37(3):3949-56. PubMed ID: 26482613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FoxP3+ regulatory T cells in peripheral blood of patients with epithelial ovarian cancer.
    Erfani N; Hamedi-Shahraki M; Rezaeifard S; Haghshenas M; Rasouli M; Samsami Dehaghani A
    Iran J Immunol; 2014 Jun; 11(2):105-12. PubMed ID: 24975967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer.
    Yamagami W; Susumu N; Tanaka H; Hirasawa A; Banno K; Suzuki N; Tsuda H; Tsukazaki K; Aoki D
    Int J Gynecol Cancer; 2011 Dec; 21(9):1628-34. PubMed ID: 21897268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance.
    Winkler I; Wilczynska B; Bojarska-Junak A; Gogacz M; Adamiak A; Postawski K; Darmochwal-Kolarz D; Rechberger T; Tabarkiewicz J
    J Ovarian Res; 2015 Jun; 8():39. PubMed ID: 26077607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.
    Lundgren S; Berntsson J; Nodin B; Micke P; Jirström K
    J Ovarian Res; 2016 Apr; 9():21. PubMed ID: 27048364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
    Watanabe Y; Katou F; Ohtani H; Nakayama T; Yoshie O; Hashimoto K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):744-52. PubMed ID: 20303300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
    Hampras SS; Sucheston-Campbell LE; Cannioto R; Chang-Claude J; Modugno F; Dörk T; Hillemanns P; Preus L; Knutson KL; Wallace PK; Hong CC; Friel G; Davis W; Nesline M; Pearce CL; Kelemen LE; Goodman MT; Bandera EV; Terry KL; Schoof N; Eng KH; Clay A; Singh PK; Joseph JM; Aben KK; Anton-Culver H; Antonenkova N; Baker H; Bean Y; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Cook LS; Cramer DW; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Despierre E; Dicks E; Doherty JA; du Bois A; Dürst M; Easton D; Eccles D; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Gronwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hogdall C; Hogdall E; Hosono S; Iversen ES; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kellar M; Kelley JL; Kiemeney LA; Klapdor R; Kolomeyevskaya N; Krakstad C; Kjaer SK; Kruszka B; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Liu S; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Moes-Sosnowska J; Narod SA; Nedergaard L; Nevanlinna H; Nickels S; Olson SH; Orlow I; Weber RP; Paul J; Pejovic T; Pelttari LM; Perkins B; Permuth-Wey J; Pike MC; Plisiecka-Halasa J; Poole EM; Risch HA; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schmitt K; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Tangen IL; Teo SH; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; Tyrer J; van Altena AM; Vergote I; Vierkant RA; Walsh C; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Gayther SA; Ramus SJ; Sellers TA; Schildkraut JM; Phelan CM; Berchuck A; Chenevix-Trench G; Cunningham JM; Pharoah PP; Ness RB; Odunsi K; Goode EL; Moysich KB
    Oncotarget; 2016 Oct; 7(43):69097-69110. PubMed ID: 27533245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cytokines secreted by CD4
    Ke X; Shen L
    Scand J Immunol; 2019 Feb; 89(2):e12736. PubMed ID: 30485902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients.
    Nowak M; Głowacka E; Lewkowicz P; Banasik M; Szyłło K; Zimna K; Bednarska K; Klink M
    Immunobiology; 2018 Jan; 223(1):1-7. PubMed ID: 29017822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast activation proteins-α suppress tumor immunity by regulating T cells and tumor-associated macrophages.
    Hou CM; Qu XM; Zhang J; Ding TT; Han W; Ji GC; Zhong ZH; Chen H; Zhang F
    Exp Mol Pathol; 2018 Feb; 104(1):29-37. PubMed ID: 29273462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
    Bachmayr-Heyda A; Aust S; Heinze G; Polterauer S; Grimm C; Braicu EI; Sehouli J; Lambrechts S; Vergote I; Mahner S; Pils D; Schuster E; Thalhammer T; Horvat R; Denkert C; Zeillinger R; Castillo-Tong DC
    BMC Cancer; 2013 Sep; 13():422. PubMed ID: 24044611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report.
    Cannioto RA; Sucheston-Campbell LE; Hampras S; Goode EL; Knutson K; Ness R; Modugno F; Wallace P; Szender JB; Mayor P; Hong CC; Joseph JM; Friel G; Davis W; Nesline M; Eng KH; Edwards RP; Kruszka B; Schmitt K; Odunsi K; Moysich KB
    Int J Gynecol Cancer; 2017 Jan; 27(1):11-16. PubMed ID: 27759594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
    Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
    Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?
    Yildirim N; Akman L; Acar K; Demir S; Ozkan S; Alan N; Zekioglu O; Terek MC; Ozdemir N; Ozsaran A
    Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():55-61. PubMed ID: 28601728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
    deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
    Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.